The analysis of the prevalence of cardiovascular disease of patients who have chronic hepatitis C at the age of late maturity was carried out against the background of standard antiviral therapy with Pegylated interferon and ribavirin in comparison with the control group, statistically comparable by age and sex with the first group before treatment. All the patients underwent the following examinations: dynamic monitoring of the arterial tension level, 12-lead electrocardiogram. According to the testimony Holter’s monitoring was done. The research results show stable increase of cardiovascular diseases in the study group in the course of treatment in comparison with control group as well as exacerbation of the diseases which the patients had before treatment with the development of complications caused by age of patients. That fact proves the need for elaboration of preventive measures when assigning the etiotropic treatment with Pegylated interferon and ribavirin of people older than 45 years.